BoltzGen Democratizes AI Therapeutic Design, Expands Druggable Universe
The open-source model designs therapeutics across "any" modality with experimental validation for diverse real-world challenging targets.
The latest Boltz open-source model, as reported by Fay Lin, PhD, designs therapeutics across "any" modality with experimental validation for diverse real-world challenging targets.
Since Boltz-1 debuted in November 2024, the Massachusetts Institute of Technology (MIT) research team has been pushing forward a new standard in open-source AI-based drug discovery, achieving AlphaFold 3-level accuracy in predicting the 3D structure of biomolecular complexes.
"any" modality with experimental validation for diverse real-world challenging targets
Author's summary: BoltzGen advances AI therapeutic design.